Mission and background

DanPET AB was founded 2012.01.11 by the former VP for medicinal chemistry at NeuroSearch A/S, Dan Peters and committed to develop future biomarkers and orphan medicines in new areas where there is an unmet need, in collaboration with World Leading Partners.

Technology and Business

Major business areas: • PET-ligands for science, development and diagnosis • [3H]-ligands as biomarkers in collaboration with Novandi Chemistry AB • Medicinal candidates in development.
Targets: • Nicotine Receptors – major focus on alpha6 and 7 • Monoamine Transporters – major focus on norepinephrine reuptake transporter (NET). Major disease areas: • Alzheimer’s disease • Parkinson’s disease /Huntington’s disease • Attention deficit hyperactivity disorder • Cancer • Imaging of vulnerable plaques.

Products, preclinical

• NS10712 (PD/HD) • NS12877 (AD) • [18F]NS14490 Artherosclerosis • [11C]NS8880 (ADHD/AD) • [18F]NS12137 (ADHD/AD) • [11C]NS14492 (AD) • [18F]NS10743 (AD) and marketing corresponding precursors, references for PET and the following tritium compounds in alliance with Novandi Chemistry AB: • [3H]NS14492 (AD) • [3H]NS10743 and • [3H]NS6784.

Highlights

DanPET will continue to add new, hot products to its pipeline - the nicotinic PAMs: • [3H]NS1738 and • [3H]NS9283 will soon be offered. DanPET plan to apply for two orphan designations. DanPET will continue to invent new opportunities like PET imaging of vulnerable plaques in artherosclerosis.

Alliance strategy

We offer: • Top modern preclinical PET-ligands and drug candidates available for out-licensing. •Collaboration within exclusive areas, joint programs and/or fee for service. •Collaboration with University and Institute with goal to build new science and knowledge and jointly publish.

Contact • Dan Peters, Ph.D., CEO, founder of DanPET AB • Rosenstigen 7, 216 19 Malmö, SWEDEN
• Mobile: +46 76 130 1903 • Website: www.danpet.eu • Email: info@danpet.eu